Digital inhalers are currently being assessed in clinical studies and some have recently been introduced on the market. Indeed, digital inhalers could help in management of multiple medication nonadherence behaviours, yet real-world data on digital inhaler use are largely lacking. Importantly, these data could further guide optimal, cost-effective implementation of digital inhalers in routine daily practice.
To fulfill this unmet need, MAECON has developed a real-world data registry that tracks medication adherence and asthma outcomes of patients using a digital inhaler. The development of the Adherence and digital inhaler Utilization in a Registry to assess Outcomes in Real-world patients with Asthma (AURORA) registry followed a phased process and closely adhered to the European Medicines Agency (EMA) Guideline on registry-based studies.
Funding: Novartis, Switzerland
Link to publications:
Wiertz M, et al. Adherence and digital inhaler Utilization in a Registry to assess Outcomes in Real-world patients with Asthma (AURORA) – A modified Delphi process. Poster presentation at the European Respiratory Society Research Seminar entitled “Digital technologies to enhance respiratory medication adherence and outcomes” (Lisbon, Portugal, May 27–28, 2022)
